We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · March 15, 2018

Ribociclib for the Treatment of HR+, HER2− Advanced Breast Cancer

Expert Review of Anticancer Therapy


Additional Info

Disclosure statements are available on the authors' profiles:

Expert Review of Anticancer Therapy
Ribociclib for the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Expert Rev Anticancer Ther 2018 Mar 01;18(3)201-213, HA Burris

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading